ATM gene inactivation in mantle cell lymphoma mainly occurs by truncating mutations and missense mutations involving the phosphatidylinositol-3 kinase domain and is associated with increasing numbers of chromosomal imbalances

被引:120
作者
Camacho, E
Hernández, L
Hernández, S
Tort, F
Bellosillo, B
Beà, S
Bosch, F
Montserrat, E
Cardesa, A
Fernández, PL
Campo, E
机构
[1] Univ Barcelona, Hosp Clin Barcelona, Pathol Lab,Dept Anat Pathol, Inst Invest Biomed August Pi & Sunyer, E-08036 Barcelona, Spain
[2] Univ Barcelona, Hosp Clin Barcelona, Pathol Lab,Dept Hematol, Inst Invest Biomed August Pi & Sunyer, E-08036 Barcelona, Spain
[3] Univ Salamanca, CSIC, Ctr Invest Canc, E-37008 Salamanca, Spain
关键词
D O I
10.1182/blood.V99.1.238
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
The ataxia-telangiectasia mutated (ATM) gene codifies for a protein critically involved in the cellular response to DNA damage. ATM alterations have been observed in some sporadic lymphoproliferative disorders. The recurrent 11q22-23 deletions found in mantle cell lymphoma (MCL) suggest that ATM could be inactivated in these lymphomas. In this study, ATM gene alterations and protein expression were examined in 20 and 17 MCL tumor specimens, respectively. Previously, these patients had been examined for p53 and p14(ARF) gene status and analyzed by comparative genomic hybridization. Nine patients had 11q22-23 losses. Eight ATM gene mutations were detected in 7 patients. These alterations were 3 missense mutations in the phosphatidyl-inositol-3 kinase (PI-3K) domain and 5 truncating mutations, including 3 frameshifts, a nonsense mutation, and a substitution of the initial methionine. All truncating mutations were associated with lack of protein expression. Somatic origin was demonstrated in 3 mutations, whereas one mutation was carried heterozygously in the patient germ line. Chromosomal imbalances were significantly higher in typical MCL with ATM inactivation (7.8 +/- 1.3) than in tumors with the wildtype gene (3 +/- 1.1) (P = .001). Moreover, tumors with bi-allelic ATM alteration were associated with 3q gains (P = .015) and frequent extranodal Involvement (P = .049). ATM gene alterations were not related to the histologic variant of the tumors, p53/p14(ARF) gene status, survival, or other clinicopathologic features of the patients. These findings Indicate that ATM gene mutations In MCL are mainly truncating or missense mutations Involving the PI-3K domain, and that may play a role In the pathogenesis of a subset of these tumors with increased numbers of chromosomal Imbalances.
引用
收藏
页码:238 / 244
页数:7
相关论文
共 48 条
[21]   p53 gene mutations and protein overexpression are associated with aggressive variants of mantle cell lymphomas [J].
Hernandez, L ;
Fest, T ;
Cazorla, M ;
TeruyaFeldstein, J ;
Bosch, F ;
Peinado, MA ;
Piris, MA ;
Montserrat, E ;
Cardesa, A ;
Jaffe, ES ;
Campo, E ;
Raffeld, M .
BLOOD, 1996, 87 (08) :3351-3359
[22]   NONPARAMETRIC-ESTIMATION FROM INCOMPLETE OBSERVATIONS [J].
KAPLAN, EL ;
MEIER, P .
JOURNAL OF THE AMERICAN STATISTICAL ASSOCIATION, 1958, 53 (282) :457-481
[23]   ATM associates with and phosphorylates p53: mapping the region of interaction [J].
Khanna, KK ;
Keating, KE ;
Kozlov, S ;
Scott, S ;
Gatei, M ;
Hobson, K ;
Taya, Y ;
Gabrielli, B ;
Chan, D ;
Lees-Miller, SP ;
Lavin, MF .
NATURE GENETICS, 1998, 20 (04) :398-400
[24]   The genetic defect in ataxia-telangiectasia [J].
Lavin, MF ;
Shiloh, Y .
ANNUAL REVIEW OF IMMUNOLOGY, 1997, 15 :177-202
[25]  
LIU Q, 1995, BIOTECHNIQUES, V18, P470
[26]   Sensing and responding to DNA damage [J].
Lowndes, NF ;
Murguia, JR .
CURRENT OPINION IN GENETICS & DEVELOPMENT, 2000, 10 (01) :17-25
[27]   Ataxia telangiectasia-mutated phosphorylates Chk2 in vivo and in vitro [J].
Matsuoka, S ;
Rotman, G ;
Ogawa, A ;
Shiloh, Y ;
Tamai, K ;
Elledge, SJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2000, 97 (19) :10389-10394
[28]  
Monni O, 1998, GENE CHROMOSOME CANC, V21, P298, DOI 10.1002/(SICI)1098-2264(199804)21:4<298::AID-GCC3>3.0.CO
[29]  
2-U
[30]   CONSERVATISM OF APPROXIMATION SIGMA (O - E)2/E IN LOGRANK TEST FOR SURVIVAL DATA OR TUMOR INCIDENCE DATA [J].
PETO, R ;
PIKE, MC .
BIOMETRICS, 1973, 29 (03) :579-584